We Claim:

1. A topical formulation comprising 0.0025% to 2% (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable salt thereof, 2% to 9% hexylene glycol, quantum satis (qs) white petrolatum, 5% to 9% mono- and di-glycerides, and 3% to 7% paraffin wax, wherein the topical formulation is essentially free of butylated hydroxytoluene and wherein the topical formulation has 3.0% w/w or less degradant diol at 0 to 6 months at 5°C to 40°C.

2. The topical formulation according to claim 1, comprising 5% hexylene glycol, 7% mono- and diglycerides, and 5% paraffin wax.

3. The topical formulation according to claim 1 or claim 2, comprising 0.005% to 1.0% (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable salt thereof.

4. The topical formulation according to claim 2, comprising 0.005% to 0.5% (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable salt thereof.

5. The topical formulation according to claim 2, comprising 0.01% (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable salt thereof.

6. A topical formulation comprising 0.01% (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable salt thereof, 5% hexylene glycol, quantum satis white petrolatum, 7% mono- and di-glycerides, and 5 paraffin wax, wherein the topical formulation is essentially free of butylated hydroxytoluene and wherein the topical formulation has 1.0% w/w or less degradant diol at 0 to 6 months at 5°C to 40°C.

7. A topical formulation comprising 0.01% (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable salt thereof, 5% hexylene glycol, quantum satis white petrolatum, 7% mono- and di-glycerides, and 5% paraffin wax, wherein the topical formulation is essentially free of butylated hydroxytoluene and wherein the topical formulation has 1.0% w/w or less degradant diol at 0 to 12 months at 5°C to 25°C.

8. Use of a compound in the manufacture of a medicament for the treatment of~~A method for treating~~ a disease or condition, wherein the medicament is a topical formulation comprising:

0025% to 2% (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable salt thereof;

2% to 9% hexylene glycol;

quantum satis (qs) white petrolatum;

5% to 9% mono- and di-glycerides; and

3% to 7% paraffin wax,

wherein the topical formulation is essentially free of butylated hydroxytoluene,

wherein the topical formulation has 3.0% w/w or less degradant diol at 0 to 6 months at 5°C to 40°C,

wherein the disease or condition is selected from the group consisting of psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, erythrodermic psoriasis, and inverse psoriasis, and

wherein a therapeutically effective amount of the topical formulation is to be administered ~~in comprising administering to the subject a~~ a subject in need of such treatment ~~a therapeutically effective amount of the topical formulation according to claim 1~~.

9. The ~~method~~use according to claim 8, wherein the disease or condition is psoriasis.

10. The ~~method~~use according to claim 8, wherein the disease or condition is plaque psoriasis.

11. Use of a compound in the manufacture of a medicament for the treatment of~~A method for treating~~ a disease or condition,

wherein the medicament is a topical formulation comprising:

0025% to 2% (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable salt thereof;

2% to 9% hexylene glycol;

quantum satis (qs) white petrolatum;

5% to 9% mono- and di-glycerides; and

3% to 7% paraffin wax,

wherein the topical formulation is essentially free of butylated hydroxytoluene,

wherein the topical formulation has 3.0% w/w or less degradant diol at 0 to 6 months at 5°C to 40°C,

wherein the disease or condition is selected from the group consisting of eczema, atopic dermatitis, hand dermatitis, contact dermatitis, allergic contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acne, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagi-harada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, and hidradenitis suppurativa,

wherein a therapeutically effective amount of the topical formulation is to be administered ~~in a subject comprising administering~~ to ~~the~~a subject in need of such treatment ~~a therapeutically effective amount of the topical formulation according to claim 1~~.

12. The ~~method~~use according to claim 11, wherein the disease or condition is atopic dermatitis.

13. The ~~method~~use according to claim 11, wherein the disease or condition is eczema.